Introduction
In the 1940s and 1950s clinicians and researchers were recognizing that lung cancer was increasing at alarming rates (Auerbach et al., 1957; Burney, 1959; Cornfield et al., 1959) . Diseases such as lung cancer were rare before the widespread use of tobacco, and so it was relatively simple for them to relate lung cancer to smoking. Today, cigarette use is the major cause of morbidity and mortality in developed countries, increasing all cause mortality. Tobacco smoke contains hundreds of known and probable human carcinogens. Smoking is associated with cancer rates in virtually every organ of the body including the lung, oral cavity, esophagus, colon, pancreas, bladder, bone marrow, cervix and kidney.
While there is a lot of data that allows us to understand the effects of smoking on lung cancer, there are still many important questions that remain unanswered. For example, why do only some smokers get lung cancer while others do not? We do not know why people need a specific level of nicotine and the optimal ways to foster cessation. For persons who cannot quit, we need to know if it is possible to lower their exposures sufficiently to reduce the risk of lung cancer. This concept is known as 'harm reduction' and there are several strategies being considered (Table 1) . The use of biomarkers is critical to answering these questions. Biomarkers are intuitively more informative and better disease risk markers when measured in the target tissue through biopsies. However, biomarker assays are technically limited and target tissue is difficult to obtain, especially in non-diseased smokers. Therefore, biomarker assays also are being developed for use in surrogate tissues. While these are technically simpler to use and the tissue (e.g. expired breath, saliva, blood and urine) is easier to collect, the ability to prove a predictive value is more difficult. Examples of biomarkers, many of which will be described below, are shown in Table 2 .
The introduction of low 'tar' and 'nicotine' cigarettes was conceptualized to make cigarettes 'safer', but currently available scientific data suggests that potential benefits may not be realized for some or most persons (see below under lung cancer). In actuality, many persons who smoke low 'tar' and 'nicotine' cigarettes compensate for lower nicotine delivery by smoking more (Benowitz et al., 1983 (Benowitz et al., , 1986a (Benowitz et al., , 1998 Ebert et al., 1983; Gritz et al., 1983) . Exposures do not seem to be different for lower tar users who compensate (Djordjevic et al., 1995 (Djordjevic et al., , 1997 .
Reducing exposure by restricting cigarette intake results in a higher peak nicotine level per cigarette and a lesser proportional reduction in urinary mutagenicity (Benowitz et al., 1986a,b; Sorsa et al., 1984) . In one study, sister chromatid exchange levels, which have not been validated as a surrogate marker for the harm, do not change when persons switch from high to low 'tar' cigarettes (Djordjevic et al., 1997) , but the relation of this marker to short term and long term exposures, half-lives and other factors that might confound such studies are not known.
Exposure to tobacco carcinogens
The use of tobacco products, as they are intended to be used, results in the exposure to more than 100 mutagens and carcinogens Zaridze et al., 1991) . Mainstream smoke consists of particulate and vapor phases. The particulate phase contains over 3500 compounds, of which at least 55 have been identified as possible human carcinogens . The vapor phase contains more than 500 compounds . Specific chemicals in tobacco smoke include polycyclic aromatic hydrocarbons (PAHs), Nnitrosamines, aromatic amines, ethylene oxide, 1,3-butadiene and others. A recent critical review summarizing data for tobacco constituents proposed that tobacco-specific nitrosamines (TSNs) and PAHs are classes of compounds that most affect human cancer risk (Hecht, 1999a) . Tobacco and tobacco products have changed over time when assessed using the Federal Trade Commission (FTC) method . However, it is known that the FTC method is inaccurate for predicting actual human exposure (Djordjevic et al., 2000; Hoffmann and Hoffmann, 1997) . Because people smoke to maintain a certain level of nicotine, many will compensate and smoke harder (depth and duration of inhalation) and will cover ventilation holes in order to get more nicotine. This results in actual higher exposure.
People are commonly exposed to PAHs through tobacco products, diet, occupation and consumption of fossil fuels (i.e. burning coal or wood). These compounds are mutagenic and carcinogenic in experimental animals (including the lung) and humans ; International Agency on the Research of Cancer, 1986; van Delft et al., 1998) . They are formed from the incomplete pyrolysis of tobacco leaves and many types of PAHs are present in tobacco smoke as a complex mixture. Parent PAHs can be detected in human lung tissue (Lodovici et al., 1998; Seto et al., 1993) . PAHs are metabolically activated in humans through CYP1A1, CYP1B1 and CYP3A4 (Kim et al., 1998; Shimada et al., 1996) , and conjugated for excretion by glutathione-S-transferases, sulfuronyl transferases and glucuronyl transferases (Robertson et al., 1988) . There are genetic variants (polymorphisms) in these genes, and this variability predicts susceptibility (see below). In humans, there is more than a 100-fold variation in the resultant capacity for DNA adduct formation (Harris et al., 1974) . PAHrelated DNA adducts have been demonstrated in human lung (Kato et al., 1995) .
N-nitrosamines (Brunnemann et al., 1996; Fischer et al., 1989 Fischer et al., , 1990 Tricker et al., 1991) are among the most potent rodent carcinogens (Lewis et al., 1997) ; they cause cancer in more than 40 animal species and 
Method Comment
Reducing the number of cigarettes smoked per day Methods such as concurrent use of nicotine replacement therapy or the use of chewing tobacco might replace some of the nicotine from cigarettes that allow a smoker to decrease their cigarette use.
Cigarette-like devices
The tobacco industry has recently introduced new products with purported decreased delivery of carcinogens. Whether this leads to actual decrease in exposure and harm remains to be determined.
Chemoprevention
Many agents reduce exposure at the cellular level, such as anti-oxidants. (Hecht, 1999b) . In humans, TSN metabolites can be detected in urine and the adducts are found in blood (Atawodi et al., 1998; Hecht et al., 1993; Parsons et al., 1998; Ronai et al., 1993; Tiano et al., 1994) . N-nitrosamines undergo metabolic activation by human cytochrome P450s located in the lung, buccal mucosa and other tissues (e.g. CYP2E1 and CYP2A6) (Hecht, 1998; Smith et al., 1992 Smith et al., , 1995 . TSNs form three different classes of DNA adducts (Hecht, 1999b) . The first is methylation of different nucleotides, which also are formed by other N-nitrosamines, and some of these adducts are more promutagenic than others (O 6 -methyl guanine more readily causes mutations than N 7 -methyl guanine), and there are different repair enzymes for each. The other class of adducts formed by TSNs, which are bulky adducts (Atawodi et al., 1998; Hecht, 1999a) , are probably repaired by nucleotide excision repair and recombination repair, similar to PAHs. Lower 'tar' and 'nicotine' cigarettes result in greater exposure to TSNs than high 'tar' and 'nicotine' (Brunnemann et al., 1996; Hoffmann and Hoffmann, 1997) , because when people smoke harder to get more nicotine, the higher burning temperatures create more TSNs. Oxidative DNA damage is the the third type of DNA adducts formed from TSNs (Hecht, 1999b) .
Pathobiological effects and the clues to etiology
The biologically effective dose (Perera, 1987 ) is frequently referred to as an intermediate biomarker of cancer risk. Commonly studied is the level of carcinogen-DNA adducts, which represents the net effect of toxic metabolic activation, lack of detoxification, lack of repair or control mechanisms and lack of cell death. In humans, tobacco smoking leads to increased adduct formation in target tissues such as the lung (Phillips et al., 1988; Schoket et al., 1998; Wiencke et al., 1995) and in surrogate tissues such as the blood (Tang et al., 1995; Vineis et al., 1994; Wiencke et al., 1995) . Evidence exists that carcinogen-DNA adduct levels are affected by genetic predispositions (Badawi et al., 1995; Grinberg-Funes et al., 1994; Kato et al., 1995; Pastorelli et al., 1998; Rojas et al., 1998; Ryberg et al., 1997; Stern et al., 1993) . Several types of studies indicate that carcinogen-DNA adducts are related to cancer risk. Case -control studies of the lung show a positive relationship (Dunn et al., 1991; Peluso et al., 1998; Tang et al., 1995; Van Schooten et al., 1990) . Only a single prospective study has been conducted, and this one indicated that higher levels of blood adducts was associated with later lung cancer risk (Tang et al., 2001) . The relationship of surrogate markers such as carcinogen-DNA adducts in blood to the target organ has been partially studied, indicating that blood levels might reflect target organ levels (Bardeesy et al., 1994; Mustonen et al., 1993; Wada et al., 1993) , but this is not yet well established.
Biomarkers of harm can range from isolated early changes with or without effects on function to events that clearly lead to carcinogenesis and can be observed in cancer cells. Chromosomal damage can be measured using classical cytogenetic methods, micronuclei formation (Schmid, 1975; Xue et al., 1992) , COMET (Poli et al., 1999; Speit and Hartmann, 1999) , fluorescent in situ hybridization, or PCR methods assessing loss of heterozygosity (using tandem repeats or comparative genomic hybridization) where the latter two methods can be used for morphologically appearing cells. Use of mutations in reporter genes, such as HPRT (Bailar, 1999; Hou et al., 1999) or GPA have been used, but it is better to identify mutation rates in cancer susceptibility genes such as p53 (Brennan et al., 1995; Valkonen and Kuusi, 1998) or K-ras (Scott et al., 1997; Slebos et al., 1991; Valkonen and Kuusi, 1998; Yakubovskaya et al., 1995) . For p53, it has been reported that there is a dose response relationship between tobacco smoking and p53 mutations in general (Kondo et al., 1996) and for G to T transversions in particular (Kure et al., 1996; Takagi et al., 1998) . Women have more G to T transversions than men for similar levels of smoking, even though men have p53 mutations more commonly (Kondo et al., 1996; Kure et al., 1996) . Interestingly, given that the p53 mutational spectrum for lung cancer is similar worldwide (Hartmann et al., 1997) , it is likely that tobacco smoke is the major determinant of lung p53 mutations worldwide. Recent studies have been focusing on the association of smoking with hypermethylation of promoter regions of tumor suppressor genes, which is seen in both current and former smokers (Palmisano et al., 2000) .
Genetic susceptibility
It stands to reason that if the color of our hair and eyes are different, then the way we respond to our environment is also different, and clearly this response is due to inherited and acquired traits. For example, while the basic color of our hair is inherited, an exposure such as the sun may modify this color. There are different ways that genetic traits may happen through genetic polymorphisms. There may be single nucleotide base substitutions (single nucleotide polymorphisms also known as SNPs) that result in amino acid substitution or stop gene expression. Several bases may be deleted or inserted, or large parts of a gene may be deleted or amplified. In general, a genetic polymorphism occurs in about every 500 bases, so that every gene will have a genetic polymorphism; but most have no effect on gene function from one person to another. The ways that genetic polymorphisms can affect lung cancer risk includes effects on smoking behavior and nicotine addiction, carcinogen metabolism, carcinogen detoxification, DNA repair, cell cycle control, apoptosis, signal transduction, and virtually every other part of cellular function and response. Acquired traits are those that have altered genetic expression, but were not inherited. An example is enzyme induction following carcinogen exposure or receptor signaling.
The area of genetics traits and nicotine addiction has been receiving a lot of recent attention. There is data to implicate dopamine reward pathways in relation to being a smoker, number of cigarettes smoked per day and in conjunction with depression (Comings et al., 1996; Lerman et al., 1998 Lerman et al., , 1999 Noble et al., 1994; Sabol et al., 1999; Shields et al., 1998; Spitz et al., 1998) . Also, there is wide interindividual variation in nicotine metabolism, for example to CYP2A6, and so to maintain a minimal blood nicotine level, CYP2A6 function might cause one person to smoke more cigarettes because of faster nicotine metabolism.
For lung cancer risk, among the most commonly studied low penetrant genes are CYP1A1 and glutathione-S-transferase M1 (GSTM1). The CYP1A1 oxidation is the first step in the metabolic activation of PAHs. Several CYP1A1 genetic polymorphisms have been identified. A recent meta-analysis has indicated that a genetic polymorphism revealed with the MSPI enzyme does affect risk (Toniolo, personal communication; Shields, 1998) . Studies of Japanese subjects indicate the importance of CYP1A1 in lung cancer risk, especially because the combination of the 'at risk' allele yielded similar odds ratios in lower smokers compared with the 'low risk' allele and heavy smoking (Nakachi et al., 1991; Okada et al., 1995) . GSTM1 is a detoxifying enzyme that catalyzes the conjugation of PAHs to glutathione. Expression of GSTM1 is inherited as an autosomal dominant trait and the cause of low GSTM1 activity is due to a critical part of the gene being deleted, such that no active protein is expressed. The low activity allele has been related to lung cancer risk in most studies . There is a polymorphism in the GSTM1 for persons who have the entire gene, but this has not been related to altered risk. Gene-gene interactions for CYP1A1 and GSTM1 have been found in ongoing Japanese studies of lung cancer (Nakachi et al., 1993) . The low activity GSTM1 also has been associated with increased PAH-DNA adducts in human lung tissue (Kato et al., 1995) , increased sister chromatid exchange and mutagenicity of lung microsomes.
Gender differences in lung cancer risk
There are data to indicate that the risk of lung cancer is about a twofold greater risk in women than men for similar cigarette smoking levels (Risch et al., 1993; Zang and Wynder, 1996) although some have not seen an increased risk (Doll and Peto, 1976; Halpern et al., 1993) . Today, women more commonly have adenocarcinoma, while men more commonly have squamous cell cancers (Ernster, 1996) , although the latter is changing. This is due to smoking different types of cigarettes (Haldorsen and Grimsrud, 1999; Levi et al., 1987; Shopland et al., 1991; Thun et al., 1997) . Because of smoking cessation occurring earlier among men and later uptake of smoking among women, lung cancer rates have been decreasing for men but not for women (Wingo et al., 1999) . While some might hypothesize that the difference in cancer risks between men and women are due to differing baseline nonsmoking rates (Prescott et al., 1998) , this was found not to be the case using summary statistics from several large cohort studies (Risch et al., 1994) . Corroborative evidence comes from the observation that there is a higher risk for lung cancer in women at similar ages of initiation, and the risks are the same in women over the age of 25 years compared to men over the age of 20 years (Hegmann et al., 1993) . There are several explanations for the observation of a woman's increased risk. One is because of the increased use of light tar and nicotine cigarettes that cause more adenocarcinoma, which is related to the greater level of tobacco specific nitrosamines and also an increased depth of inhalation Thun et al., 1997) . Another explanation for a higher risk might be related to biological differences between men and women, where there is a more frequent occurrence of estrogen and progesterone receptors in women lung tumors (Kaiser et al., 1996) . Corroborative evidence for a hormonal relationship comes from the observation that Chinese women have a higher risk of lung cancer if they have more and shorter menstrual cycles (Gao et al., 1987) . Separately, women have higher levels of carcinogen-DNA adducts in lung tissues, even though they have the same or lower levels of smoking (Ryberg et al., 1994) and while the frequency of p53 mutations is higher in men than women, they also more frequently have G to T p53 transversions (Kure et al., 1996) , suggesting a particular susceptibility to tobacco smoke carcinogens. Women might also be more susceptible if they have particular metabolic polymorphisms affecting carcinogen detoxification (Mollerup et al., 1999; Rennard et al., 1990; Ryberg et al., 1997; Tang et al., 1998) . Separately, gastrinreleasing peptide has been shown to be more highly expressed in women versus men for the same level of smoking (Shriver et al., 2000) . This gene is located on the X chromosome and so a double copy might result in increased levels that in turn triggers growth stimulation (Sidney et al., 1995) .
Environmental tobacco smoke
Environmental tobacco smoke (ETS), also termed passive smoking or exposure to second-hand smoke, has been estimated to cause 2600 to 7400 lung cancer deaths per year among non-smokers in the US, according to a review of nine studies of lung cancer mortality (Repace and Lowrey, 1990) .
There is widespread concurrence for the relation of ETS to lung cancer (Brownson et al., 1997 (Brownson et al., , 1998 NCI Expert Committee, 2000; Sunyer et al., 1996; Zeise et al., 1997) . Numerous other studies support the conclusion that ETS exposure increases lung cancer risk (Brownson et al., 1992 (Brownson et al., , 1998 Darby and Pike, 1988; Stockwell et al., 1992; Tweedie and Mengersen, 1992) . Potential biases in the ETS literature have been noted (Lee, 1998) , but even biomarker studies support the relationship (Tweedie and Mengersen, 1992) . These types of study can demonstrate the effect due to misclassification of ETS exposure. A study of two large cohorts in Sweden, one involving twins and the other of randomly surveyed adults in the population, estimated that about 5% of former smokers were misclassified as never smoked, with roughly equal proportions in men and women. The RR for lung cancer among misclassified men was 1.9 (95% CI 0.5 -9.1), indicating no statistical association, compared to 4.5 for correctly classified former smokers and 13.3 for current smokers (Nyberg et al., 1997) . The authors of that study concluded that misclassification occurs mainly among very light smokers and long-term exsmokers. Improved methodologies have shown that ETS exposed persons have elevated levels of TSN metabolites in their urine (Hecht 1999a ). Other studies have reported an increase for aryl aromatic aminerelated adducts (Maclure et al., 1989) .
Perspectives
There is incontrovertible evidence that tobacco smoking causes cancer in humans. If so, then it is reasonable to ask 'Why do we need to study tobacco smoking and isn't it better to put our resources into preventing smoking initiation and encouraging cessation?' First, it must be recognized that many smokers are unable to quit due to their addiction. Thus, we need better prevention strategies. For example, the tobacco industry are increasingly marketing products purported to reduce exposure and imply that this will be associated with a decreased risk. This method of 'harm reduction' needs to be closely evaluated because of its potential significant public health benefits and significant risks. For example, these products might be more harmful, as we learned to be the case for light tar and nicotine cigarettes. Another reason to continue to study lung carcinogenesis is because of the need for preventive strategies in former smokers. In spite of successfully quitting, and while the risk of lung cancer decreases after smoking cessation, the risk never returns to that for non-smokers (Halpern et al., 1993) . Thus, we owe to these successful individuals to help prevent a disease from occurring. Finally, the study of smoking and lung cancer will allow us to understand other types of cancer risks and carcinogenesis. For example, many tobacco smoke carcinogens are also present in the diet and workplace, but will be easier to study in smokers because of a presumably easier way to quantitate exposure.
There is a significant effort ongoing to understand the role of genetic predispositions for lung cancer risk. We have learned that genetics affects risks in many ways, including having an influence on smoking behavior, metabolism, repair and other cellular responses. Undoubtedly, we will continue to learn more about all these areas.
